| Role |
Name |
Disclosure |
Details |
| Author | Noah S Scheinfeld, MD, JD, FAAD, Assistant Clinical Professor, Department of Dermatology, Columbia University; Consulting Staff, Department of Dermatology, St Luke's Roosevelt Hospital Center, Beth Israel Medical Center, New York Eye and Ear Infirmary; Private Practice | Optigenex | Details | | Coauthor | Orin M Goldblum, MD, Consulting Staff, Department of Medicine, Division of Dermatology, University of Pittsburgh Medical Center South Side | Nothing to disclose | Details | | Medical Editor | Harold S Rabinovitz, MD, Clinical Professor, Department of Dermatology, University of Miami School of Medicine | Nothing to disclose | Details | | Pharmacy Editor | David F Butler, MD, Professor of Dermatology, Texas A&M University College of Medicine; Director, Division of Dermatology, Scott and White Clinic; Director Dermatology Residency Training Program, Scott and White Clinic | 3M Pharmaceutical Graceway Pharmaceuticals | Details | | Managing Editor | Amanda Oakley, MBChB, FRACP, Clinical Director, Clinical Associate Professor, Department of Dermatology, Waikato Hospital, Hamilton, New Zealand | Nothing to disclose | Details | | CME Editor | Catherine Quirk, MD, Clinical Assistant Professor, Department of Dermatology, Brown University | Nothing to disclose | Details | | Chief Editor | Dirk M Elston, MD, Director, Department of Dermatology, Geisinger Medical Center | Nothing to disclose | Details |
Contributor Disclosure
Contributor:
|
Contributor Disclosure: |
| Orin M Goldblum, Coauthor |
The contributor discloses no conflict of interest. |
Contributor Disclosure
Contributor:
|
Contributor Disclosure: |
| Harold S Rabinovitz, Medical Editor |
The contributor discloses no conflict of interest. |
|